๐ค AI Summary
This study addresses the frequent challenges of convergence difficulties and inferential bias in mixed-effects models for repeated measures (MMRM) under small-sample settings, multiple time points, and uncertainty in covariance structure selection. The authors propose a novel modeling strategy that integrates an empirically bias-corrected covariance estimator with a heterogeneous autoregressive covariance structure. Through extensive Monte Carlo simulations and analysis of a diabetes clinical trial dataset, they systematically evaluate various MMRM configurations. Their findings indicate that the proposed approach achieves high convergence rates and near-nominal confidence interval coverage in moderate-to-large samples. In small-sample scenarios, a parsimonious model incorporating baseline covariates and treatmentโtime interaction terms substantially improves both convergence and estimation efficiency, offering a robust and practical modeling framework for longitudinal analysis in clinical trials.
๐ Abstract
Mixed models for repeated measures (MMRM) are a popular method for analyzing longitudinal data in clinical trials. However, practical challenges, such as small sample sizes, large numbers of time points, and selection of variance-covariance structure for within-subject errors, often present barriers to model convergence and valid inference. This article evaluates different options for using MMRM in different scenarios through extensive simulation studies and an application on diabetes trial data. We demonstrate that the empirical bias-reduced coefficient covariance adjustment with the heterogeneous autoregressive covariance structure yields near-nominal coverage with high convergence rates for moderate and large sample designs. For small sample sizes, the simple model with baseline covariates and treatment by time point interaction achieves good efficiency and high probability of convergence. Based on these results, we provide practitioners with actionable guidance for applying MMRM to clinical trial data.